
### Accepted Manuscript

Title: Immuno-oncology from the perspective of somatic evolution

Authors: Santiago González, Nadezda Volkova, Philip Beer, Moritz Gerstung



PII:	S1044-579X(17)30214-6
DOI:	https://doi.org/10.1016/j.semcancer.2017.12.001
Reference:	YSCBI 1421
To appear in:	Seminars in Cancer Biology
Received date:	5-9-2017
Revised date:	29-11-2017
Accepted date:	5-12-2017

Please cite this article as: González Santiago, Volkova Nadezda, Beer Philip, Gerstung Moritz.Immuno-oncology from the perspective of somatic evolution.*Seminars in Cancer Biology* https://doi.org/10.1016/j.semcancer.2017.12.001

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## ACCEPTED MANUSCRIPT

# Immuno-oncology from the perspective of somatic evolution

Santiago González<sup>a,\*</sup>, Nadezda Volkova<sup>a,\*</sup>, Philip Beer<sup>b,#</sup> and Moritz Gerstung<sup>a,#</sup>

- a. European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK
- b. Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, UK

\* These authors contributed equally

# To whom correspondence should be addressed:

Moritz Gerstung European Molecular Biology Laboratory European Bioinformatics Institute (EMBL-EBI), Hinxton, Cambridgeshire, CB10 1SD, United Kingdom. Tel: +44 (0) 1223 49 4636, email: moritz.gerstung@ebi.ac.uk

Philip Beer Wellcome Trust Sanger Institute Hinxton, Cambridgeshire, CB10 1SD, United Kingdom. email: pbeer@doctors.org.uk

#### Abstract

The past years have witnessed significant success for cancer immunotherapies that activate a patient's immune system against their cancer cells. At the same time our understanding of the genetic changes driving tumor evolution have progressed dramatically. The study of cancer genomes has shown that tumors are best understood as cell populations governed by the rules of evolution, leading to the emergence and spread of cell lineages with pathogenic mutations. Moreover, somatic evolution can explain the acquisition of mutations conferring drug resistance in the ever-lasting battle for reaching even fitter cell states. Here, we review the current state of the art of somatic cancer evolution and mechanisms of immune control and escape. We also revisit the principles of immunotherapy from the perspective of somatic evolution and discuss the basic rules of resistance to immunotherapies as dictated by evolution. Download English Version:

## https://daneshyari.com/en/article/10156988

Download Persian Version:

https://daneshyari.com/article/10156988

Daneshyari.com